FGF-1 for Peripheral Arterial Disease

This trial tests a new treatment called FGF-1, a growth factor therapy, for individuals with peripheral arterial disease who experience leg pain while walking, known as intermittent claudication. Researchers aim to determine if FGF-1 can improve blood flow and reduce symptoms compared to a placebo, which contains no active drug. Individuals who have experienced leg pain while walking for at least six months and have been stable for the last three months might be suitable candidates. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works and measuring its effectiveness in an initial, smaller group of participants.

Research has shown that FGF-1 is generally safe for people. In one study involving Parkinson's disease patients, FGF-1 was administered nasally and was found to be safe and well-tolerated, with no major side effects. Another study injected FGF-1 into the heart muscle of patients with coronary artery disease, and it also demonstrated safety, with no serious adverse events.

Unlike the standard treatments for Peripheral Arterial Disease (PAD), which typically involve lifestyle changes, medications like cilostazol or aspirin, and sometimes surgical interventions, FGF-1 offers a novel approach. Researchers are excited about FGF-1 because it works by promoting angiogenesis, which is the formation of new blood vessels, directly addressing the reduced blood flow characteristic of PAD. Additionally, the intramuscular injection method of FGF-1 provides a targeted delivery system that could enhance its effectiveness compared to systemic medications. These unique features of FGF-1 could potentially improve blood flow more efficiently and offer a new lifeline to those suffering from PAD.

Research has shown that FGF-1, a protein known as fibroblast growth factor 1, might improve blood flow in conditions like peripheral arterial disease. Studies have found that FGF-1 can help form new blood vessels and boost circulation. Other research suggests that FGF-1 may also enhance heart function and protect the heart after damage. This indicates that FGF-1 could potentially ease symptoms like intermittent claudication, which is pain from reduced blood flow to the limbs. Early findings also show that FGF-1 is well-tolerated in humans, a positive sign for its potential use in treatment. Participants in this trial will receive either FGF-1 at varying doses or a placebo to further evaluate its effectiveness and safety.⁶⁷⁸⁹¹⁰